You Shouldn't Ignore Gilead's Idelalisib Motley Fool In early September, Gilead filed a new drug application with the Food and Drug Administration for idelalisib as a treatment for iNHL patients who fail to respond to treatment from current go-to drug rituximab -- marketed as Rituxan by Biogen Idec ... |
